MacroGenics’ mission is to discover, develop and deliver to patients novel biologics for the treatment of cancer, autoimmune disorders and infectious diseases.  Learn More

  MacroGenics' Corporate Fact Sheet

Product Pipeline Highlights

View full chart
Program (Target) Indication Lead Opt. Pre-
Clin.		 Ph
1		 Ph
2		 Ph
3
ONCOLOGY          
MGAH22 (Anti-HER2)MGAH22 (Anti-HER2)(HER2) Solid Tumors *  *  *  *  * 
MGA271 (Anti-B7-H3)MGA271 (Anti-B7-H3)(B7-H3) Solid Tumors *  *  *  *  * 
OtherOther Solid Tumors *  *  *  *  * 
OtherOther Liquid Tumors *  *  *  *  * 
OtherOther(>70 Targets) Solid & Liq. Tumors *  *  *  *  * 
AUTOIMMUNE          
Teplizumab (Anti-CD3)(CD3) T1D - Early Onset *  *  *  *  * 
T1D - At-Risk *  *  *  *  * 
OtherOther(CD32BxCD79) Inflammation *  *  *  *  * 
OtherOther Autoimmune *  *  *  *  * 
INFECTIOUS DISEASES          
OtherOther Emerging Diseases *  *  *  *  * 
* In global collaboration with Eli Lilly & Co.

Overview

Since its founding in 2000, MacroGenics has applied its world-class antibody capabilities to create life-changing medicines. The company’s innovative product candidates leverage its fully-integrated capabilities and its multiple, proprietary technology platforms.

 Learn more

Company Highlights

  • Robust pipeline in oncology, autoimmunity and infectious diseases
  • Partners include Boehringer Ingelheim, Pfizer and Servier
  • Fully-integrated biologics capabilities across product development process 
  • Strong financial position and blue-chip investor base
  • Experienced management team and highly collaborative corporate culture 
Learn more

Teplizumab: Phase 3 Data Published

Phase 3 data and exploratory post-hoc analyses published in The Lancet.
Learn more: teplizumab
Learn more: The Lancet

Partnering


In December 2011, MacroGenics announced an option for a license collaboration with Servier on MGA271.
In October 2010, MacroGenics announced two global partnerships around its DART platform. Learn more